RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Fosun Pharma announced it will make a $17.6 million investment into EOS Imaging of France. EOS concentrates on the orthopedic imaging market, making 2D/3D imaging devices that limit dosing for patient safety along with imaging and surgical planning software. After the investment, Fosun will own 13% of EOS, and it will help EOS expand its sales in China, the company’s third largest market after the EU and the US. Fosun will have a EOS board seat.
Source: China Biotoday
